Response to comment on Goldfine et al. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes care 2013;36:4132-4139.
Corresponding author: Mark A. Creager, mcreager@partners.org.
Allison B
AB
Goldfine
Kathleen A
KA
Jablonski
Steven E
SE
Shoelson
Mark A
MA
Creager
D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D004730:Endothelium, Vascular / Q000503:physiopathology*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D008297:Male; D012459:Salicylates / Q000008:administration & dosage*; D014664:Vasodilation / Q000187:drug effects*
D001786:Blood Glucose; D012459:Salicylates